Article ID Journal Published Year Pages File Type
5671780 Clinical Microbiology and Infection 2017 4 Pages PDF
Abstract
TW4-response indicates the probability of achieving SVR12 to currently used DAA-based therapy in HCV genotype 3-infected individuals with cirrhosis. This finding may be useful to tailor treatment strategy in this setting.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Microbiology
Preview
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Authors
, , , , , , , , , , , , , ,